Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

Similar articles for PubMed (Select 24798160)

1.

BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.

Ilie MI, Long-Mira E, Hofman V, Mouroux J, Vignaud JM, Gauchotte G, Begueret H, Merlio JP, Emile JF, Hébuterne X, Hofman P.

Pathology. 2014 Jun;46(4):311-5. doi: 10.1097/PAT.0000000000000113.

PMID:
24798160
2.

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.

Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P.

Ann Oncol. 2013 Mar;24(3):742-8. doi: 10.1093/annonc/mds534. Epub 2012 Nov 6.

3.

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.

PMID:
24085553
4.

Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.

Adackapara CA, Sholl LM, Barletta JA, Hornick JL.

Histopathology. 2013 Aug;63(2):187-93. doi: 10.1111/his.12154. Epub 2013 Jun 13.

PMID:
23763264
5.

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.

Sasaki H, Shimizu S, Tani Y, Shitara M, Okuda K, Hikosaka Y, Moriyama S, Yano M, Fujii Y.

Lung Cancer. 2013 Oct;82(1):51-4. doi: 10.1016/j.lungcan.2013.06.014. Epub 2013 Aug 5.

PMID:
23927882
6.

Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.

Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.

Am J Surg Pathol. 2014 Sep;38(9):1235-41. doi: 10.1097/PAS.0000000000000229.

PMID:
24832158
7.

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.

Løes IM, Immervoll H, Angelsen JH, Horn A, Geisler J, Busch C, Lønning PE, Knappskog S.

Tumour Biol. 2015 Feb;36(2):1003-13. doi: 10.1007/s13277-014-2711-5. Epub 2014 Oct 16.

8.

Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.

Kuan SF, Navina S, Cressman KL, Pai RK.

Hum Pathol. 2014 Mar;45(3):464-72. doi: 10.1016/j.humpath.2013.10.026. Epub 2013 Nov 4.

PMID:
24529329
9.

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA.

Am J Surg Pathol. 2013 Mar;37(3):413-20. doi: 10.1097/PAS.0b013e318271249e.

PMID:
23211290
10.

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.

Acta Neuropathol. 2011 Jul;122(1):11-9. doi: 10.1007/s00401-011-0841-z. Epub 2011 Jun 3.

PMID:
21638088
11.

BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.

Bledsoe JR, Kamionek M, Mino-Kenudson M.

Am J Surg Pathol. 2014 Oct;38(10):1418-28. doi: 10.1097/PAS.0000000000000263.

PMID:
24921639
12.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
13.

Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.

Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.

Thyroid. 2014 May;24(5):858-66. doi: 10.1089/thy.2013.0302. Epub 2014 Mar 6.

PMID:
24417277
14.

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA.

Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.

PMID:
23026937
15.

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W.

Pathol Int. 2014 Dec;64(12):601-6. doi: 10.1111/pin.12215. Epub 2014 Oct 31.

PMID:
25359093
16.

VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.

Sajanti S, Sirniö P, Väyrynen JP, Tuomisto A, Klintrup K, Mäkelä J, Ristimäki A, Mäkinen MJ.

Virchows Arch. 2014 Jun;464(6):637-43. doi: 10.1007/s00428-014-1555-0. Epub 2014 Apr 11.

PMID:
24722974
17.

Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.

Mesteri I, Bayer G, Meyer J, Capper D, Schoppmann SF, von Deimling A, Birner P.

Mod Pathol. 2014 Jan;27(1):135-44. doi: 10.1038/modpathol.2013.126. Epub 2013 Jul 26.

18.

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.

Hum Pathol. 2013 Nov;44(11):2563-70. doi: 10.1016/j.humpath.2013.06.018. Epub 2013 Sep 24.

PMID:
24071017
19.

BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.

Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M.

Int J Cancer. 2013 Oct 1;133(7):1624-30. doi: 10.1002/ijc.28183. Epub 2013 Apr 25.

PMID:
23553055
20.

BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.

Affolter K, Samowitz W, Tripp S, Bronner MP.

Genes Chromosomes Cancer. 2013 Aug;52(8):748-52. doi: 10.1002/gcc.22070. Epub 2013 May 7.

PMID:
23650027
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk